Article Text

Download PDFPDF
Original article
Airflow limitation in people living with HIV and matched uninfected controls
  1. Andreas Ronit1,
  2. Jens Lundgren2,
  3. Shoaib Afzal3,
  4. Thomas Benfield4,
  5. Ashley Roen5,
  6. Amanda Mocroft5,
  7. Jan Gerstoft1,
  8. Børge G Nordestgaard3,6,
  9. Jørgen Vestbo7,
  10. Susanne D Nielsen1
  11. on behalf of the Copenhagen Co-morbidity in HIV infection (COCOMO) study group
  1. 1 Viro-immunology Research Unit, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
  2. 2 CHIP, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
  3. 3 The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark
  4. 4 Department of Infectious Diseases, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark
  5. 5 Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK
  6. 6 Faculty of Health and Medical Sciences, Copenhagen University Hospital, Copenhagen, Denmark
  7. 7 Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK
  1. Correspondence to Dr Susanne D Nielsen, Viro-immunology Research Unit, Department of Infectious Diseases, Copenhagen University Hospital, Copenhagen 2200, Denmark; sdn{at}dadlnet.dk

Footnotes

  • Contributors AnR was responsible for concept, data collection, and statistical analysis, and drafted the manuscript. JL, TB, JG, BGN and JV were responsible for concept and have had content review and editing input. SA was partly responsible for statistical analysis and has had content review and editing input. AR and AM had content review and editing input, and provided statistical support. SDN was the project leader, was responsible for concept and data collection, and has had content review and editing input.

  • Funding This work was supported by Rigshospitalet Research Council, Region Hovedstaden, the Lundbeck Foundation, the Novo Nordisk Foundation, and the Danish National Research Foundation grant 126. The study was designed, conducted, analysed and written by the authors without involvement of any commercial party.

  • Competing interests AnR: Travelling grants from Gilead. TB: Personal fees from Bristol Myers Squibb (BMS) and from Gilead and non-financial support from BMS, and from Gilead. AsR: No conflicts of interests. AM: Honoraria, lecture fees and travel support from BMS, BI, Pfizer, Merck, ViiV and Wragge. JG: Honoraria for consulting and presenting paid to his institution from Gilead, Abbvie, ViiV, BMS, MSD, Janssen and Medivir. JV: Honoraria for consulting and presenting from AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaskoSmithKline and Novartis. SDN: Unrestricted research grants from the Novo Nordisk Foundation, the Lundbeck Foundation and the Rigshospitalet Research Council; travelling grants from Gilead, MSD, BMS and GSK/ViiV; advisory board activity for Gilead and GSK/ViiV.

  • Ethics approval The study was approved by the Regional Ethics Committee of Copenhagen (COCOMO: H-15017350; CGPS: H-KF-01-144/01). Written informed consent was obtained from all participants.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors AnR was responsible for concept, data collection, and statistical analysis, and drafted the manuscript. JL, TB, JG, BGN and JV were responsible for concept and have had content review and editing input. SA was partly responsible for statistical analysis and has had content review and editing input. AR and AM had content review and editing input, and provided statistical support. SDN was the project leader, was responsible for concept and data collection, and has had content review and editing input.

  • Funding This work was supported by Rigshospitalet Research Council, Region Hovedstaden, the Lundbeck Foundation, the Novo Nordisk Foundation, and the Danish National Research Foundation grant 126. The study was designed, conducted, analysed and written by the authors without involvement of any commercial party.

  • Competing interests AnR: Travelling grants from Gilead. TB: Personal fees from Bristol Myers Squibb (BMS) and from Gilead and non-financial support from BMS, and from Gilead. AsR: No conflicts of interests. AM: Honoraria, lecture fees and travel support from BMS, BI, Pfizer, Merck, ViiV and Wragge. JG: Honoraria for consulting and presenting paid to his institution from Gilead, Abbvie, ViiV, BMS, MSD, Janssen and Medivir. JV: Honoraria for consulting and presenting from AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaskoSmithKline and Novartis. SDN: Unrestricted research grants from the Novo Nordisk Foundation, the Lundbeck Foundation and the Rigshospitalet Research Council; travelling grants from Gilead, MSD, BMS and GSK/ViiV; advisory board activity for Gilead and GSK/ViiV.

  • Ethics approval The study was approved by the Regional Ethics Committee of Copenhagen (COCOMO: H-15017350; CGPS: H-KF-01-144/01). Written informed consent was obtained from all participants.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Airwaves
    The Triumvirate